BioVentix PLC – Results for the year ended 30 June 2019

BioVentix PLC – Results for the year ended 30 June 2019

Bioventix plc (BVXP), a UK company specialising in the development and commercial supply of high-affinity monoclonal antibodies for applications in clinical diagnostics, announces its audited results for the year ended 30 June 2019.

Highlights:

  • Revenue up 6% to £9.3 million
  • Profit before tax up 1% to £7.0 million
  • Cash down £0.5 million to £6.5 million
  • Second interim dividend of 43p per share (2018: 36p)
  • Special dividend of 47p per share (2018: 55p)
No Comments

Post a Comment